Another study provided evidence that knockdown of RRM2 enhances the antitumor efficiency of sunitinib and anti-PD-1 therapy in renal cancer [54], which further supported the potential role of RRM2 as a target to facilitate therapeutic resistance. Here, RRM2 is linked to renal carcinoma.